Several parameters for predicting survival in patients with colorectal cancer have been identified, including the performance status, age, gender and tumor-nodemetastasis(TNM) stage. Although the TNM stage is importan...Several parameters for predicting survival in patients with colorectal cancer have been identified, including the performance status, age, gender and tumor-nodemetastasis(TNM) stage. Although the TNM stage is important and useful for predicting the prognosis and determining the appropriate treatment, it is well known that the survival time varies widely, even in patients with the same stage of disease. Therefore, the identification of new parameters capable of more precisely predicting patient survival is needed to help select the optimal treatment, especially in patients in the advanced stage of disease. Although the TNM stage reflects the tumor characteristics, cancer progression and survival are not determined solely based on the local characteristics of the tumor, but also the host systemic immune/inflammatory response. Therefore, using a combination of parameters that reflect both tumor characteristics and the host systemic inflammatory status is thought to be important for accurately predicting patient survival.展开更多
目的探讨黄芪仙灵脾汤联合活血通脉片对肾病综合征高凝血症患者血清CRP、TNF-α及血液流变学的影响。方法收集2014年3月—2016年2月于浙江省台州医院住院或门诊治疗的肾病综合征高凝血症患者78例,按随机数字表法分为2组,每组39例,对照...目的探讨黄芪仙灵脾汤联合活血通脉片对肾病综合征高凝血症患者血清CRP、TNF-α及血液流变学的影响。方法收集2014年3月—2016年2月于浙江省台州医院住院或门诊治疗的肾病综合征高凝血症患者78例,按随机数字表法分为2组,每组39例,对照组采用强的松、低分子肝素钙治疗;观察组在此基础上采用黄芪仙灵脾汤联合活血通脉片治疗,共治疗2个月为1个疗程,对比2组间临床疗效,治疗前后血液流变学、CRP、TNF-α、NO、ET-1以及肾功能指标,同时记录不良反应事件。结果与治疗前比较,2组治疗后红细胞压积、红细胞聚集指数、全血黏度、血浆黏度降低,血清CRP、TNF-α、ET-1降低,血清NO升高,24 h Pro、BUN、Scr水平降低,总蛋白水平升高(均P<0.05);与对照组比较,观察组治疗后红细胞压积、红细胞聚集指数、全血黏度、血浆黏度较低,血清CRP、TNF-α、ET-1较低,血清NO较高,24 h Pro、BUN、Scr水平较低,总蛋白水平较高(均P<0.05);对照组不良反应发生率(17.95%)与观察组(23.08%)对比差异无统计学意义(P>0.05)。结论黄芪仙灵脾汤联合活血通脉片对肾病综合征高凝血症患者疗效确切,且不增加不良反应,与降低CRP、TNF-α,改善血管内皮和血液流变学相关。展开更多
文摘Several parameters for predicting survival in patients with colorectal cancer have been identified, including the performance status, age, gender and tumor-nodemetastasis(TNM) stage. Although the TNM stage is important and useful for predicting the prognosis and determining the appropriate treatment, it is well known that the survival time varies widely, even in patients with the same stage of disease. Therefore, the identification of new parameters capable of more precisely predicting patient survival is needed to help select the optimal treatment, especially in patients in the advanced stage of disease. Although the TNM stage reflects the tumor characteristics, cancer progression and survival are not determined solely based on the local characteristics of the tumor, but also the host systemic immune/inflammatory response. Therefore, using a combination of parameters that reflect both tumor characteristics and the host systemic inflammatory status is thought to be important for accurately predicting patient survival.
文摘目的探讨黄芪仙灵脾汤联合活血通脉片对肾病综合征高凝血症患者血清CRP、TNF-α及血液流变学的影响。方法收集2014年3月—2016年2月于浙江省台州医院住院或门诊治疗的肾病综合征高凝血症患者78例,按随机数字表法分为2组,每组39例,对照组采用强的松、低分子肝素钙治疗;观察组在此基础上采用黄芪仙灵脾汤联合活血通脉片治疗,共治疗2个月为1个疗程,对比2组间临床疗效,治疗前后血液流变学、CRP、TNF-α、NO、ET-1以及肾功能指标,同时记录不良反应事件。结果与治疗前比较,2组治疗后红细胞压积、红细胞聚集指数、全血黏度、血浆黏度降低,血清CRP、TNF-α、ET-1降低,血清NO升高,24 h Pro、BUN、Scr水平降低,总蛋白水平升高(均P<0.05);与对照组比较,观察组治疗后红细胞压积、红细胞聚集指数、全血黏度、血浆黏度较低,血清CRP、TNF-α、ET-1较低,血清NO较高,24 h Pro、BUN、Scr水平较低,总蛋白水平较高(均P<0.05);对照组不良反应发生率(17.95%)与观察组(23.08%)对比差异无统计学意义(P>0.05)。结论黄芪仙灵脾汤联合活血通脉片对肾病综合征高凝血症患者疗效确切,且不增加不良反应,与降低CRP、TNF-α,改善血管内皮和血液流变学相关。
